Wnt and lithium: A common destiny in the therapy of nervous system pathologies?

Cellular and Molecular Life Sciences

Volumn 71, Issue 7, 2014, Pages 1123-1148

  Meffre, Delphine ^a   Grenier, Julien ^a   Bernard, Sophie ^a   Courtin, Françoise ^a   Dudev, Todor ^b,c   Shackleford, Ghjuvan'Ghjacumu ^a   Jafarian Tehrani, Mehrnaz ^a   Massaad, Charbel ^a  

^a CNRS   (France)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

GSK3 ; Lithium; Myelination; Neuroprotection; Nuclear receptors; Wnt beta catenin pathway

Indexed keywords

BETA CATENIN; CALCIUM ION; CELL NUCLEUS RECEPTOR; DISHEVELLED PROTEIN; DOPAMINE RECEPTOR; ENDOCRINE DISRUPTOR; GLUCOCORTICOID RECEPTOR; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM SALT; LIVER X RECEPTOR; MAGNESIUM ION; MYELIN; NEUROTRANSMITTER; SODIUM ION; THYROID HORMONE RECEPTOR; WNT PROTEIN; CENTRAL DEPRESSANT AGENT; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; LITHIUM;

ACTIN FILAMENT; ALZHEIMER DISEASE; APOPTOSIS; BINDING COMPETITION; BINDING SITE; BIPOLAR DISORDER; BRAIN FUNCTION; CANAVAN DISEASE; CELL POLARITY; CELL SURVIVAL; CHOLINERGIC TRANSMISSION; CYTOSOL; DEGENERATIVE DISEASE; DEMYELINATING DISEASE; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUNTINGTON CHOREA; MENTAL DISEASE; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; NERVE INJURY; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM FUNCTION; NEUROLOGIC DISEASE; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN FUNCTION; REVIEW; SCHIZOPHRENIA; TRAUMATIC BRAIN INJURY; WNT SIGNALING PATHWAY; BIOLOGICAL MODEL; DRUG ANTAGONISM; METABOLISM; NERVOUS SYSTEM; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

BETA CATENIN; CELL POLARITY; CENTRAL NERVOUS SYSTEM DEPRESSANTS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LITHIUM; MODELS, BIOLOGICAL; NERVOUS SYSTEM; NERVOUS SYSTEM DISEASES; SYNAPTIC TRANSMISSION; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84902076914     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-013-1378-1     Document Type: Review

References (299)

1. Ciani L, Salinas PC (2005) WNTs in the vertebrate nervous system: from patterning to neuronal connectivity. Nat Rev Neurosci 6(5):351-362. doi:10.1038/nrn1665
2. Mulligan KA, Cheyette BN (2012) Wnt signaling in vertebrate neural development and function. J Neuroimmune Pharmacol 7(4):774-787. doi:10.1007/s11481-012-9404-x
3. Valvezan AJ, Klein PS (2012) GSK-3 and Wnt signaling in neurogenesis and bipolar disorder. Frontiers mol neurosci 5:1. doi:1 0.3389/fnmol.2012.00001
4. Carter M, Chen X, Slowinska B, Minnerath S, Glickstein S, Shi L, Campagne F, Weinstein H, Ross ME (2005) Crooked tail (Cd) model of human folate-responsive neural tube defects is mutated in Wnt coreceptor lipoprotein receptor-related protein 6. Proc Natl Acad Sci USA 102(36):12843-12848. doi:10.1073/pnas.0501963102
5. Kiecker C, Niehrs C (2001) A morphogen gradient of Wnt/betacatenin signalling regulates anteroposterior neural patterning in xenopus. Development 128(21):4189-4201
6. Megason SG, McMahon AP (2002) A mitogen gradient of dorsal midline Wnts organizes growth in the CNS. Development 129(9):2087-2098
7. Rosso SB, Sussman D, Wynshaw-Boris A, Salinas PC (2005) Wnt signaling through Dishevelled, Rac and JNK regulates dendritic development. Nat Neurosci 8(1):34-42. doi:10.1038/nn1374
8. Cerpa W, Gambrill A, Inestrosa NC, Barria A (2011) Regulation of NMDA-receptor synaptic transmission by Wnt signaling. J neurosci 31(26):9466-9471. doi:10.1523/JNEURO SCI.6311-10.2011
9. Budnik V, Salinas PC (2011) Wnt signaling during synaptic development and plasticity. Curr Opin Neurobiol 21(1):151-159. doi:10.1016/j.conb.2010.12.002
10. Inestrosa NC, Arenas E (2010) Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci 11(2):77-86. doi:10.1038/nrn2755
11. Fancy SP, Baranzini SE, Zhao C, Yuk DI, Irvine KA, Kaing S, Sanai N, Franklin RJ, Rowitch DH (2009) Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev 23(13):1571-1585. doi:10.1101/gad.1806309
12. Tawk M, Makoukji J, Belle M, Fonte C, Trousson A, Hawkins T, Li H, Ghandour S, Schumacher M, Massaad C (2011) Wnt/beta-catenin signaling is an essential and direct driver of myelin gene expression and myelinogenesis. J neurosci 31(10):3729-3742. doi:10.1523/JNEUROSCI.4270-10.2011
13. Ye F, Chen Y, Hoang T, Montgomery RL, Zhao XH, Bu H, Hu T, Taketo MM, Van Es JH, Clevers H, Hsieh J, Bassel-Duby R, Olson EN, Lu QR (2009) HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the beta-catenin-TCF interaction. Nat Neurosci 12(7):829-838. doi:10.1038/nn. 2333
14. Makoukji J, Belle M, Meffre D, Stassart R, Grenier J, Shackleford G, Fledrich R, Fonte C, Branchu J, Goulard M, De Waele C, Charbonnier F, Sereda MW, Baulieu EE, Schumacher M, Bernard S, Massaad C (2012) Lithium enhances remyelination of peripheral nerves. Proc Natl Acad Sci USA 109(10):3973-3978. doi:10.1073/pnas.1121367109
15. Wexler EM, Rosen E, Lu D, Osborn GE, Martin E, Raybould H, Geschwind DH (2011) Genome-wide analysis of a Wnt1-regulated transcriptional network implicates neurodegenerative pathways. Sci signal 4(193): ra65. doi:10.1126/scisig nal.2002282
16. Chuang DM, Wang Z, Chiu CT (2011) GSK-3 as a Target for Lithium-Induced Neuroprotection Against Excitotoxicity in Neuronal Cultures and Animal Models of Ischemic Stroke. Frontiers mol neurosci 4:15. doi:10.3389/fnmol.2011.00015
17. Neumann C, Cohen S (1997) Morphogens and pattern formation. BioEssays 19(8):721-729. doi:10.1002/bies.950190813
18. Du SJ, Purcell SM, Christian JL, McGrew LL, Moon RT (1995) Identification of distinct classes and functional domains of Wnts through expression of wild-type and chimeric proteins in xenopus embryos. Mol Cell Biol 15(5):2625-2634
19. Kikuchi A, Yamamoto H, Sato A (2009) Selective activation mechanisms of Wnt signaling pathways. Trends Cell Biol 19(3):119-129. doi:10.1016/j.tcb.2009.01.003
20. Angers S, Moon RT (2009) Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol 10(7):468-477. doi:10.1038/nrm2717
21. Kohn AD, Moon RT (2005) Wnt and calcium signaling: betacatenin-independent pathways. Cell Calcium 38(3-4):439-446. doi:10.1016/j.ceca.2005.06.022
22. Wu J, Mlodzik M (2009) A quest for the mechanism regulating global planar cell polarity of tissues. Trends Cell Biol 19(7):295-305. doi:10.1016/j.tcb.2009.04.003
23. Hoppler S, Kavanagh CL (2007) Wnt signalling: variety at the core. J Cell Sci 120(Pt 3):385-393. doi:10.1242/jcs.03363
24. Willert K, Logan CY, Arora A, Fish M, Nusse R (1999) A drosophila axin homolog, daxin, inhibits Wnt signaling. Development 126(18):4165-U73
25. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X, He X (2002) Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108(6):837-847
26. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R (1997) Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 16(13):3797-3804. doi:10.1093/emboj/16.13.3797
27. Stadeli R, Hoffmans R, Basler K (2006) Transcription under the control of nuclear Arm/beta-catenin. Curr Biol 16(10):R378-R385. doi:10.1016/j.cub.2006.04.019
28. Luo W, Peterson A, Garcia BA, Coombs G, Kofahl B, Heinrich R, Shabanowitz J, Hunt DF, Yost HJ, Virshup DM (2007) Protein phosphatase 1 regulates assembly and function of the betacatenin degradation complex. EMBO J 26(6):1511-1521. doi:10.1038/sj.emboj.7601607
29. Davidson G, Wu W, Shen J, Bilic J, Fenger U, Stannek P, Glinka A, Niehrs C (2005) Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction. Nature 438(7069):867-872. doi:10.1038/nature04170
30. Yokoya F, Imamoto N, Tachibana T, Yoneda Y (1999) Betacatenin can be transported into the nucleus in a Ran-unassisted manner. Mol Biol Cell 10(4):1119-1131
31. Sharma M, Jamieson C, Johnson M, Molloy MP, Henderson BR (2012) Specific armadillo repeat sequences facilitate beta-catenin nuclear transport in live cells via direct binding to nucleoporins Nup62, Nup153, and RanBP2/Nup358. J Biol Chem 287(2):819-831. doi:10.1074/jbc. M111.299099
32. Wu X, Tu X, Joeng KS, Hilton MJ, Williams DA, Long F (2008) Rac1 activation controls nuclear localization of betacatenin during canonical Wnt signaling. Cell 133(2):340-353. doi:10.1016/j.cell.2008.01.052
33. Belenkaya TY, Han C, Standley HJ, Lin X, Houston DW, Heasman J, Lin X (2002) Pygopus encodes a nuclear protein essential for wingless/Wnt signaling. Development 129(17):4089-4101
34. Mosimann C, Hausmann G, Basler K (2006) Parafibromin/hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/armadillo. Cell 125(2):327-341. doi:10.1016/j.cell.2006.01.053
35. Griffin CT, Curtis CD, Davis RB, Muthukumar V, Magnuson T (2011) The chromatin-remodeling enzyme BRG1 modulates vascular Wnt signaling at two levels. Proc Natl Acad Sci USA 108(6):2282-2287. doi:10.1073/pnas.1013751108
36. Li Z, Nie F, Wang S, Li L (2011) Histone H4 Lys 20 monomethylation by histone methylase SET8 mediates Wnt target gene activation. Proc Natl Acad Sci USA 108(8):3116-3123. doi:10.1073/pnas.1009353108
37. Sheldahl LC, Slusarski DC, Pandur P, Miller JR, Kuhl M, Moon RT (2003) Dishevelled activates Ca2 + flux, PKC, and CamKII in vertebrate embryos. J cell Biol 161(4):769-777. doi:10.1083/jcb.200211094
38. Semenov MV, Habas R, Macdonald BT, He X (2007) Snapshot: noncanonical Wnt signaling pathways. Cell 131(7):1378. doi:10.1016/j.cell.2007.12.011
39. Dissanayake SK, Wade M, Johnson CE, O'Connell MP, Leotlela PD, French AD, Shah KV, Hewitt KJ, Rosenthal DT, Indig FE, Jiang Y, Nickoloff BJ, Taub DD, Trent JM, Moon RT, Bittner M, Weeraratna AT (2007) The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem 282(23):17259-17271. doi:10.1074/jbc. M700075200
40. Veeman MT, Axelrod JD, Moon RT (2003) A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. Dev Cell 5(3):367-377
41. Moeller H, Jenny A, Schaeffer HJ, Schwarz-Romond T, Mlodzik M, Hammerschmidt M, Birchmeier W (2006) Diversin regulates heart formation and gastrulation movements in development. Proc Natl Acad Sci USA 103(43):15900-15905. doi:10.1073/pnas.0603808103
42. Tree DR, Shulman JM, Rousset R, Scott MP, Gubb D, Axelrod JD (2002) Prickle mediates feedback amplification to generate asymmetric planar cell polarity signaling. Cell 109(3):371-381
43. Narimatsu M, Bose R, Pye M, Zhang L, Miller B, Ching P, Sakuma R, Luga V, Roncari L, Attisano L, Wrana JL (2009) Regulation of planar cell polarity by Smurf ubiquitin ligases. Cell 137(2):295-307. doi:10.1016/j.cell.2009.02.025
44. Capelluto DG, Kutateladze TG, Habas R, Finkielstein CV, He X, Overduin M (2002) The DIX domain targets dishevelled to actin stress fibres and vesicular membranes. Nature 419(6908):726-729. doi:10.1038/nature01056
45. Krylova O, Messenger MJ, Salinas PC (2000) Dishevelled-1 regulates microtubule stability: a new function mediated by glycogen synthase kinase-3beta. J cell Biol 151(1):83-94
46. Liu W, Sato A, Khadka D, Bharti R, Diaz H, Runnels LW, Habas R (2008) Mechanism of activation of the Formin protein Daam1. Proc Natl Acad Sci USA 105(1):210-215. doi:10.1073/pnas.0707277105
47. Habas R, Kato Y, He X (2001) Wnt/Frizzled activation of Rho regulates vertebrate gastrulation and requires a novel Formin homology protein Daam1. Cell 107(7):843-854
48. Matusek T, Gombos R, Szecsenyi A, Sanchez-Soriano N, Czibula A, Pataki C, Gedai A, Prokop A, Rasko I, Mihaly J (2008) Formin proteins of the DAAM subfamily play a role during axon growth. J Neurosci 28(49):13310-13319. doi:10.1523/JN EUROSCI.2727-08.2008
49. Chang L, Jones Y, Ellisman MH, Goldstein LS, Karin M (2003) JNK1 is required for maintenance of neuronal microtubules and controls phosphorylation of microtubule-associated proteins. Dev Cell 4(4):521-533
50. Ciani L, Salinas PC (2007) c-Jun. N-terminal kinase (JNK) cooperates with Gsk3beta to regulate Dishevelledmediated microtubule stability. BMC Cell Biol 8:27. doi:10.1186/1471-2121-8-27
51. Zhang X, Zhu J, Yang GY, Wang QJ, Qian L, Chen YM, Chen F, Tao Y, Hu HS, Wang T, Luo ZG (2007) Dishevelled promotes axon differentiation by regulating atypical protein kinase C. Nat Cell Biol 9(7):743-754. doi:10.1038/ncb1603
52. Suzuki A, Hirata M, Kamimura K, Maniwa R, Yamanaka T, Mizuno K, Kishikawa M, Hirose H, Amano Y, Izumi N, Miwa Y, Ohno S (2004) aPKC acts upstream of PAR-1b in both the establishment and maintenance of mammalian epithelial polarity. Curr Biol 14(16):1425-1435. doi:10.1016/j. cub.2004.08.021
53. Freese JL, Pino D, Pleasure SJ (2010) Wnt signaling in development and disease. Neurobiol Dis 38(2):148-153. doi:10.1016/j.nbd.2009.09.003
54. Salcedo-Tello P, Ortiz-Matamoros A, Arias C (2011) GSK3 Function in the Brain during Development, Neuronal Plasticity, and Neurodegeneration. Int J Alzheimer's Dis 2011:189728. doi:10.4061/2011/189728
55. Salinas PC (2007) Modulation of the microtubule cytoskeleton: a role for a divergent canonical Wnt pathway. Trends Cell Biol 17(7):333-342. doi:10.1016/j.tcb.2007.07.003
56. Speese SD, Budnik V (2007) Wnts: up-and-coming at the synapse. Trends Neurosci 30(6):268-275. doi:10.1016/j. tins.2007.04.003
57. Dill J, Wang H, Zhou F, Li S (2008) Inactivation of glycogen synthase kinase 3 promotes axonal growth and recovery in the CNS. J Neurosci 28(36):8914-8928. doi:10.1523/JNEURO SCI.1178-08.2008
58. Zou Y (2004) Wnt signaling in axon guidance. Trends Neurosci 27(9):528-532. doi:10.1016/j.tins.2004.06.015
59. Wolf AM, Lyuksyutova AI, Fenstermaker AG, Shafer B, Lo CG, Zou Y (2008) Phosphatidylinositol-3-kinase-atypical protein kinase C signaling is required for Wnt attraction and anterior-posterior axon guidance. J Neurosci 28(13):3456-3467. doi:10.1523/JNEUROSCI.0029-08.2008
60. Lei Q, Jeong Y, Misra K, Li S, Zelman AK, Epstein DJ, Matise MP (2006) Wnt signaling inhibitors regulate the transcriptional response to morphogenetic Shh-Gli signaling in the neural tube. Dev Cell 11(3):325-337. doi:10.1016/j.devcel.2006.06.013
61. Li B, Kuriyama S, Moreno M, Mayor R (2009) The posteriorizing gene Gbx2 is a direct target of Wnt signalling and the earliest factor in neural crest induction. Development 136(19):3267-3278. doi:10.1242/dev. 036954
62. Braun MM, Etheridge A, Bernard A, Robertson CP, Roelink H (2003) Wnt signaling is required at distinct stages of development for the induction of the posterior forebrain. Development 130(23):5579-5587. doi:10.1242/dev. 00685
63. Chung S, Leung A, Han BS, Chang MY, Moon JI, Kim CH, Hong S, Pruszak J, Isacson O, Kim KS (2009) Wnt1-lmx1a forms a novel autoregulatory loop and controls midbrain dopaminergic differentiation synergistically with the SHH-FoxA2 pathway. Cell Stem Cell 5(6):646-658. doi:10.1016/j. stem.2009.09.015
64. Fujimura N, Vacik T, Machon O, Vlcek C, Scalabrin S, Speth M, Diep D, Krauss S, Kozmik Z (2007) Wnt-mediated downregulation of Sp1 target genes by a transcriptional repressor Sp5. J Biol Chem 282(2):1225-1237. doi:10.1074/jbc. M605851200
65. Hirabayashi Y, Itoh Y, Tabata H, Nakajima K, Akiyama T, Masuyama N, Gotoh Y (2004) The Wnt/beta-catenin pathway directs neuronal differentiation of cortical neural precursor cells. Development 131(12):2791-2801. doi:10.1242/dev. 01165
66. Su H, Zhang W, Guo J, Guo A, Yuan Q, Wu W (2009) Lithium enhances the neuronal differentiation of neural progenitor cells in vitro and after transplantation into the avulsed ventral horn of adult rats through the secretion of brainderived neurotrophic factor. J Neurochem 108(6):1385-1398. doi:10.1111/j.1471-4159.2009.05902.x
67. Kuwabara T, Hsieh J, Muotri A, Yeo G, Warashina M, Lie DC, Moore L, Nakashima K, Asashima M, Gage FH (2009) Wnt-mediated activation of NeuroD1 and retro-elements during adult neurogenesis. Nat Neurosci 12(9):1097-1105. doi:10.1038/nn. 2360
68. Wisniewska MB, Misztal K, Michowski W, Szczot M, Purta E, Lesniak W, Klejman ME, Dabrowski M, Filipkowski RK, Nagalski A, Mozrzymas JW, Kuznicki J (2010) LEF1/betacatenin complex regulates transcription of the Cav3.1 calcium channel gene (Cacna1 g) in thalamic neurons of the adult brain. Neuroscience 30(14):4957-4969. doi:10.1523/JNEURO SCI.1425-09.2010
69. Fonte C, Grenier J, Trousson A, Chauchereau A, Lahuna O, Baulieu EE, Schumacher M, Massaad C (2005) Involvement of jbetaj-catenin and unusual behavior of CBP and p300 in glucocorticosteroid signaling in Schwann cells. Proc Natl Acad Sci USA 102(40):14260-14265. doi:10.1073/pnas.0506930102
70. Matrisciano F, Busceti CL, Bucci D, Orlando R, Caruso A, Molinaro G, Cappuccio I, Riozzi B, Gradini R, Motolese M, Caraci F, Copani A, Scaccianoce S, Melchiorri D, Bruno V, Battaglia G, Nicoletti F (2011) Induction of the Wnt antagonist Dickkopf-1 is involved in stress-induced hippocampal damage. PLoS ONE 6(1):e16447. doi:10.1371/journal.pone.0016447
71. Boku S, Nakagawa S, Masuda T, Nishikawa H, Kato A, Kitaichi Y, Inoue T, Koyama T (2009) Glucocorticoids and lithium reciprocally regulate the proliferation of adult dentate gyrusderived neural precursor cells through GSK-3beta and betacatenin/TCF pathway. Neuropsychopharmacology 34(3):805-815. doi:10.1038/npp. 2008.198
72. Legrand J (1982) Thyroid hormones and maturation of the nervous system. J de physiologie 78(7):603-652
73. Bernal J (2007) Thyroid hormone receptors in brain development and function. Nat Clin Pract Endocrinol Metab 3(3):249-259. doi:10.1038/ncpendmet0424
74. Berbel P, Navarro D, Auso E, Varea E, Rodriguez AE, Ballesta JJ, Salinas M, Flores E, Faura CC, De Escobar GM (2010) Role of late maternal thyroid hormones in cerebral cortex development: an experimental model for human prematurity. Cereb Cortex 20(6):1462-1475. doi:10.1093/cercor/bhp212
75. Bauer M, Goetz T, Glenn T, Whybrow PC (2008) The thyroid-brain interaction in thyroid disorders and mood disorders. J Neuroendocrinol 20(10):1101-1114. doi: 10.1111/j.1365-2826.2008.01774.x
76. Barakat-Walter I (1999) Role of thyroid hormones and their receptors in peripheral nerve regeneration. J Neurobiol 40(4):541-559
77. Harsan LA, Steibel J, Zaremba A, Agin A, Sapin R, Poulet P, Guignard B, Parizel N, Grucker D, Boehm N, Miller RH, Ghandour MS (2008) Recovery from chronic demyelination by thyroid hormone therapy: myelinogenesis induction and assessment by diffusion tensor magnetic resonance imaging. The Journal of neuroscience: the official journal of the Society for Neuroscience 28(52):14189-14201. doi:10.1523/JNEURO SCI.4453-08.2008
78. Lemkine GF, Raj A, Alfama G, Turque N, Hassani Z, Alegria-Prevot O, Samarut J, Levi G, Demeneix BA (2005) Adult neural stem cell cycling in vivo requires thyroid hormone and its alpha receptor. FASEB J 19(7):863-865. doi:10.1096/fj.04-2916fje
79. Lopez-Juarez A, Remaud S, Hassani Z, Jolivet P, Pierre Simons J, Sontag T, Yoshikawa K, Price J, Morvan-Dubois G, Demeneix BA (2012) Thyroid hormone signaling acts as a neurogenic switch by repressing Sox2 in the adult neural stem cell niche. Cell Stem Cell 10(5):531-543. doi:10.1016/j.stem.2012.04.008
80. Bernal J, Morte B (2012) Thyroid hormone receptor activity in the absence of ligand: physiological and developmental implications. Biochim Biophys Acta. doi:10.1016/j.bbagen. 2012.04.014
81. Courtin F, Zrouri H, Lamirand A, Li WW, Mercier G, Schumacher M, Goascogne CL, Pierre M (2005) Thyroid hormone deiodinases in the central and peripheral nervous system. Thyroid 15(8):931-942. doi:10.1089/thy.2005.15.931
82. Mohacsik P, Zeold A, Bianco AC, Gereben B (2011) Thyroid hormone and the neuroglia: both source and target. J Thyroid Res 2011:215718. doi:10.4061/2011/215718
83. Kress E, Samarut J, Plateroti M (2009) Thyroid hormones and the control of cell proliferation or cell differentiation: paradox or duality? Mol Cell Endocrinol 313(1-2):36-19. doi:10.1016/j.mce.2009.08.028
84. Sirakov M, Skah S, Nadjar J, Plateroti M (2012) Thyroid hormone's action on progenitor/stem cell biology: new challenge for a classic hormone? Biochim Biophys Acta. doi:10.1016/j.bbagen. 2012.07.014
85. Natsume H, Sasaki S, Kitagawa M, Kashiwabara Y, Matsushita A, Nakano K, Nishiyama K, Nagayama K, Misawa H, Masuda H, Nakamura H (2003) Beta-catenin/Tcf-1-mediated transactivation of cyclin D1 promoter is negatively regulated by thyroid hormone. Biochem Biophys Res Commun 309(2):408-413
86. Guigon CJ, Zhao L, Lu C, Willingham MC, Cheng SY (2008) Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor. Mol Cell Biol 28(14):4598-4608. doi:10.1128/MCB.02192-07
87. Sirakov M, Skah S, Lone IN, Nadjar J, Angelov D, Plateroti M (2012) Multi-level interactions between the nuclear receptor TRalpha1 and the WNT effectors beta-catenin/Tcf4 in the intestinal epithelium. PLoS One 7(4):e34162. doi:10.1371/journal.pone.0034162
88. Wang L, Shao YY, Ballock RT (2010) Thyroid hormone-mediated growth and differentiation of growth plate chondrocytes involves IGF-1 modulation of beta-catenin signaling. J Bone Miner Res 25(5):1138-1146. doi:10.1002/jbmr.5
89. O'Shea PJ, Kim DW, Logan JG, Davis S, Walker RL, Meltzer PS, Cheng SY, Williams GR (2012) Advanced bone formation in mice with a dominant-negative mutation in the thyroid hormone receptor beta gene due to activation of Wnt/betacatenin protein signaling. J Biol Chem 287(21):17812-17822. doi:10.1074/jbc. M111.311464
90. Liao CH, Yeh CT, Huang YH, Wu SM, Chi HC, Tsai MM, Tsai CY, Liao CJ, Tseng YH, Lin YH, Chen CY, Chung IH, Cheng WL, Chen WJ, Lin KH (2012) Dickkopf 4 positively regulated by the thyroid hormone receptor suppresses cell invasion in human hepatoma cells. Hepatology 55(3):910-920. doi:10.1002/hep. 24740
91. Dentice M, Luongo C, Ambrosio R, Sibilio A, Casillo A, Iaccarino A, Troncone G, Fenzi G, Larsen PR, Salvatore D (2012) Beta-catenin regulates deiodinase levels and thyroid hormone signaling in colon cancer cells. Gastroenterology 143(4):1037-1047. doi:10.1053/j.gastro.2012.06.042
92. Miller LD, Park KS, Guo QM, Alkharouf NW, Malek RL, Lee NH, Liu ET, Cheng SY (2001) Silencing of Wnt signaling and activation of multiple metabolic pathways in response to thyroid hormone-stimulated cell proliferation. Mol Cell Biol 21(19):6626-6639
93. Zhang C (2009) Novel functions for small RNA molecules. Curr Opin Mol Ther 11(6):641-651
94. Baas D, Bourbeau D, Sarlieve LL, Ittel ME, Dussault JH, Puymirat J (1997) Oligodendrocyte maturation and progenitor cell proliferation are independently regulated by thyroid hormone. Glia 19(4):324-332
95. Chew LJ, Shen W, Ming X, Senatorov VV Jr, Chen HL, Cheng Y, Hong E, Knoblach S, Gallo V (2011) SRY-box containing gene 17 regulates the Wnt/beta-catenin signaling pathway in oligodendrocyte progenitor cells. J NeuroSci 31(39):13921-13935. doi:10.1523/JNEUROSCI.3343-11.2011
96. Russell DW (2000) Oxysterol biosynthetic enzymes. Biochim Biophys Acta 1529(1-3):126-135
97. Papassotiropoulos A, Lutjohann D, Bagli M, Locatelli S, Jessen F, Buschfort R, Ptok U, Bjorkhem I, Von Bergmann K, Heun R (2002) 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res 36(1):27-32
98. Leoni V, Masterman T, Diczfalusy U, De Luca G, Hillert J, Bjorkhem I (2002) Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis. Neurosci Lett 331(3):163-166
99. Teunissen CE, Dijkstra CD, Polman CH, Hoogervorst EL, Von Bergmann K, Lutjohann D (2003) Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients. Neurosci Lett 347(3):159-162
100. Bochelen D, Mersel M, Behr P, Lutz P, Kupferberg A (1995) Effect of oxysterol treatment on cholesterol biosynthesis and reactive astrocyte proliferation in injured rat brain cortex. J Neurochem 65(5):2194-2200
101. Trousson A, Bernard S, Petit PX, Liere P, Pianos A, El Hadri K, Lobaccaro JM, Ghandour MS, Raymondjean M, Schumacher M, Massaad C (2009) 25-hydroxycholesterol provokes oligodendrocyte cell line apoptosis and stimulates the secreted phospholipase A2 type IIA via LXR beta and PXR. J Neurochem 109(4):945-958. doi:10.1111/j.1471-4159.2009.06009.x
102. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ (1996) An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 383(6602):728-731. doi:10.1038/383728a0
103. Chen JD, Evans RM (1995) A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377(6548):454-457. doi:10.1038/377454a0
104. Huuskonen J, Fielding PE, Fielding CJ (2004) Role of p160 coactivator complex in the activation of liver X receptor. Arterioscler Thromb Vasc Biol 24(4):703-708. doi:10.1161/01. ATV.0000121202.72593.da
105. Andersson S, Gustafsson N, Warner M, Gustafsson JA (2005) Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice. Proc Natl Acad Sci USA 102(10):3857-3862. doi:10.1073/pnas.0500634102
106. Makoukji J, Shackleford G, Meffre D, Grenier J, Liere P, Lobaccaro JM, Schumacher M, Massaad C (2011) Interplay between LXR and Wnt/beta-catenin signaling in the negative regulation of peripheral myelin genes by oxysterols. J Neurosci 31(26):9620-9629. doi:10.1523/JNEUROSCI.0761-11.2011
107. Shackleford G, Makoukji J, Grenier J, Liere P, Meffre D, Massaad C (2013) Differential regulation of Wnt/beta-catenin signaling by Liver X Receptors in Schwann cells and oligodendrocytes. Biochem Pharmacol. doi:10.1016/j.bcp. 2013.02.036
108. Chuu CP (2011) Modulation of liver X receptor signaling as a prevention and therapy for colon cancer. Med Hypotheses 76(5):697-699. doi:10.1016/j.mehy.2011.01.037
109. Uno S, Endo K, Jeong Y, Kawana K, Miyachi H, Hashimoto Y, Makishima M (2009) Suppression of beta-catenin signaling by liver X receptor ligands. Biochem Pharmacol 77(2):186-195. doi:10.1016/j.bcp. 2008.10.007
110. El-Mallakh RS (2004) Ion homeostasis and the mechanism of action of lithium. Clin Neurosci Res 4:227-231
111. Huang X, Lei Z, El-Mallakh RS (2007) Lithium normalizes elevated intracellular sodium. Bipolar Disord 9(3):298-300. doi:10.1111/j.1399-5618.2007.00429.x
112. Baumann P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, Uehlinger C, Kasas A, Amey M, Jonzier-Perey M (1996) A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 16(4):307-314
113. Chenu F, Bourin M (2006) Potentiation of antidepressant-like activity with lithium: mechanism involved. Curr Drug Targets 7(2):159-163
114. Quiroz JA, Machado-Vieira R, Zarate CA Jr, Manji HK (2010) Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology 62(1):50-60. doi:10.1159/000314310
115. De Freitas DM, Castro MMCA, Geraldes CF (2006) Is competitive between Li + and Mg2 + the underlying theme in the proposed mechanisms for the pharmacological action of lithium salts in bipolar disorder? Acc Chem Res 39:283-291
116. Jope RS (2003) Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 24(9):441-143. doi:10.1016/S0165-6147 (03) 00206-2
117. Ryves WJ, Harwood AJ (2001) Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 280(3):720-725. doi:10.1006/b brc.2000.4169
118. Haimovich A, Eliav U, Goldbourt A (2012) Determination of the lithium binding site in inositol monophosphatase, the putative target for lithium therapy, by magic-angle-spinning solid-state NMR. J Am Chem Soc 134(12):5647-5651. doi:10.1021/ja211794x
119. Leech AP, Baker GR, Shute JK, Cohen MA, Gani D (1993) Chemical and kinetic mechanism of the inositol monophosphatase reaction and its inhibition by Li+. Eur J Biochem/FEBS 212(3):693-704
120. Dudev T, Lim C (2011) Competition between Li + and Mg2 + in metalloproteins. Implications for lithium therapy. J Am Chem Soc 133(24):9506-9515. doi:10.1021/ja201985s
121. Lu SY, Jiang YJ, Zou JW, Wu TX (2011) Dissection of the difference between the group I metal ions in inhibiting GSK3beta: a computational study. Phys Chem Chem Phys 13(15):7014-7023. doi:10.1039/c0cp02498h
122. Ciani L, Boyle KA, Dickins E, Sahores M, Anane D, Lopes DM, Gibb AJ, Salinas PC (2011) Wnt7a signaling promotes dendritic spine growth and synaptic strength through Ca (2) (+)/Calmodulin-dependent protein kinase II. Proc Natl Acad Sci USA 108(26):10732-10737. doi:10.1073/pnas.1018132108
123. Yu X, Malenka RC (2003) Beta-catenin is critical for dendritic morphogenesis. Nat Neurosci 6(11):1169-1177. doi:10.1038/nn1132
124. Beaulieu JM, Gainetdinov RR, Caron MG (2009) Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 49:327-347. doi:10.1146/annurev. pharmtox. 011008.145634
125. Urs NM, Snyder JC, Jacobsen JP, Peterson SM, Caron MG (2012) Deletion of GSK3beta in D2R-expressing neurons reveals distinct roles for beta-arrestin signaling in antipsychotic and lithium action. Proc Natl Acad Sci USA 109(50):20732-20737. doi:10.1073/pnas.1215489109
126. Du J, Wei Y, Liu L, Wang Y, Khairova R, Blumenthal R, Tragon T, Hunsberger JG, Machado-Vieira R, Drevets W, Wang YT, Manji HK (2010) A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. Proc Natl Acad Sci USA 107(25):11573-11578. doi:10.1073/p nas.0913138107
127. Caldero J, Brunet N, Tarabal O, Piedrafita L, Hereu M, Ayala V, Esquerda JE (2010) Lithium prevents excitotoxic cell death of motoneurons in organotypic slice cultures of spinal cord. Neuroscience 165(4):1353-1369. doi:10.1016/j. neuroscience.2009.11.034
128. Zhu LQ, Wang SH, Liu D, Yin YY, Tian Q, Wang XC, Wang Q, Chen JG, Wang JZ (2007) Activation of glycogen synthase kinase-3 inhibits long-term potentiation with synapse-associated impairments. J Neurosci 27(45):12211-12220. doi:10.152 3/JNEUROSCI.3321-07.2007
129. Hashimoto R, Takei N, Shimazu K, Christ L, Lu B, Chuang DM (2002) Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 43(7):1173-1179
130. Kopnisky KL, Chalecka-Franaszek E, Gonzalez-Zulueta M, Chuang DM (2003) Chronic lithium treatment antagonizes glutamate-induced decrease of phosphorylated CREB in neurons via reducing protein phosphatase 1 and increasing MEK activities. Neuroscience 116(2):425-435
131. Berger-Sweeney J (2003) The cholinergic basal forebrain system during development and its influence on cognitive processes: important questions and potential answers. Neurosci Biobehav Rev 27(4):401-U1
132. Ahn Allen CG (2012) The role of the alpha7 nicotinic receptor in cognitive processing of persons with schizophrenia. Curr opin Psychiatry 25(2):103-108. doi:10.1097/YCO.0b0 13e3283503637
133. Thomsen MS, Weyn A, Mikkelsen JD (2011) Hippocampal alpha7 nicotinic acetylcholine receptor levels in patients with schizophrenia, bipolar disorder, or major depressive disorder. Bipolar Disord 13(7-8):701-707. doi:10.1111/j.1399-5618.2011.00961.x
134. Langmead CJ, Watson J, Reavill C (2008) Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther 117(2):232-243. doi:10.1016/j.pharmthera.2007.09.009
135. Farias GG, Valles AS, Colombres M, Godoy JA, Toledo EM, Lukas RJ, Barrantes FJ, Inestrosa NC (2007) Wnt-7a induces presynaptic colocalization of alpha 7-nicotinic acetylcholine receptors and adenomatous polyposis coli in hippocampal neurons. J Neurosci 27(20):5313-5325. doi:10.1523/JNEURO SCI.3934-06.2007
136. Jensen M, Hoerndli FJ, Brockie PJ, Wang R, Johnson E, Maxfield D, Francis MM, Madsen DM, Maricq AV (2012) Wnt signaling regulates acetylcholine receptor translocation and synaptic plasticity in the adult nervous system. Cell 149(1):173-187. doi:10.1016/j.cell.2011.12.038
137. Beurel E, Jope RS (2006) The paradoxical pro- and antiapoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 79(4):173-189. doi:10.1016/j.pneurobio.2006.07.006
138. Bielecka AM, Obuchowicz E (2008) Antiapoptotic action of lithium and valproate. Pharmacol Rep 60(6):771-782
139. Ngok-Ngam P, Watcharasit P, Thiantanawat A, Satayavivad J (2013) Pharmacological inhibition of GSK3 attenuates DNA damage-induced apoptosis via reduction of p53 mitochondrial translocation and Bax oligomerization in neuroblastoma SH-SY5Y CELLS. Cell Mol Biol Lett 18(1):58-74. doi:10.2478/s11658-012-0039-y
140. Chiu CT, Chuang DM (2010) Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther 128(2):281-304. doi:10.1016/j.phar mthera.2010.07.006
141. Lazarus JH (2009) Lithium and thyroid. Best Pract Res Clin Endocrinol Metab 23(6):723-733. doi:10.1016/j.beem.2009.06.002
142. St Germain DL (1987) Regulatory effect of lithium on thyroxine metabolism in murine neural and anterior pituitary tissue. Endocrinology 120(4):1430-1438
143. Baumgartner A, Pinna G, Hiedra L, Gaio U, Hessenius C, Campos-Barros A, Eravci M, Prengel H, Thoma R, Meinhold H (1997) Effects of lithium and carbamazepine on thyroid hormone metabolism in rat brain. Neuropsychopharmacology 16(1):25-41. doi:10.1016/S0893-133X (96) 00144-3
144. Eravci M, Pinna G, Meinhold H, Baumgartner A (2000) Effects of pharmacological and nonpharmacological treatments on thyroid hormone metabolism and concentrations in rat brain. Endocrinology 141(3):1027-1040
145. Pinna G, Broedel O, Eravci M, Stoltenburg-Didinger G, Plueckhan H, Fuxius S, Meinhold H, Baumgartner A (2003) Thyroid hormones in the rat amygdala as common targets for antidepressant drugs, mood stabilizers, and sleep deprivation. Biol Psychiatry 54(10):1049-1059
146. Hahn CG, Pawlyk AC, Whybrow PC, Gyulai L, Tejani-Butt SM (1999) Lithium administration affects gene expression of thyroid hormone receptors in rat brain. Life Sci 64(20):1793-1802
147. Hahn CG, Pawlyk AC, Whybrow PC, Tejani-Butt SM (1999) Differential expression of thyroid hormone receptor isoforms by thyroid hormone and lithium in rat GH3 and B103 cells. Biol Psychiatry 45(8):1004-1012
148. Lin YF, Huang MC, Liu HC (2012) Glycogen synthase kinase 3beta gene polymorphisms may be associated with bipolar I disorder and the therapeutic response to lithium. J Affect Disord. doi:10.1016/j.jad.2012.08.025
149. Lachman HM, Pedrosa E, Petruolo OA, Cockerham M, Papolos A, Novak T, Papolos DF, Stopkova P (2007) Increase in GSK-3beta gene copy number variation in bipolar disorder. Am J Med Genet Part B, Neuropsychiatric Genet 144B (3):259-265. doi:10.1002/ajmg.b.30498
150. Bearden CE, Thompson PM, Dalwani M, Hayashi KM, Lee AD, Nicoletti M, Trakhtenbroit M, Glahn DC, Brambilla P, Sassi RB, Mallinger AG, Frank E, Kupfer DJ, Soares JC (2007) Greater cortical gray matter density in lithium-treated patients with bipolar disorder. Biol Psychiatry 62(1):7-16. doi:10.1016/j.biopsych.2006.10.027
151. Chuang DM, Manji HK (2007) In search of the Holy Grail for the treatment of neurodegenerative disorders: has a simple cation been overlooked? Biol Psychiatry 62(1):4-6. doi:10.1016/j.biopsych.2007.04.008
152. O'Brien WT, Harper AD, Jove F, Woodgett JR, Maretto S, Piccolo S, Klein PS (2004) Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci 24(30):6791-6798. doi:10.1523/JNEURO SCI.4753-03.2004
153. Omata N, Chiu CT, Moya PR, Leng Y, Wang Z, Hunsberger JG, Leeds P, Chuang DM (2011) Lentivirally mediated GSK-3beta silencing in the hippocampal dentate gyrus induces antidepressant-like effects in stressed mice. The international journal of neuropsychopharmacology/official scientific journal of the Collegium Internationale Neuropsychopharmacologicum 14(5):711-717. doi:10.1017/S1461145710000726
154. Gould TD, Einat H, O'Donnell KC, Picchini AM, Schloesser RJ, Manji HK (2007) Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology 32(10):2173-2183. doi:10.1038/sj.npp. 1301338
155. Polter A, Beurel E, Yang S, Garner R, Song L, Miller CA, Sweatt JD, McMahon L, Bartolucci AA, Li X, Jope RS (2010) Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology 35(8):1761-1774. doi:10.1038/npp. 2010.43
156. Prickaerts J, Moechars D, Cryns K, Lenaerts I, Van Craenendonck H, Goris I, Daneels G, Bouwknecht JA, Steckler T (2006) Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J Neuroscience 26(35):9022-9029. doi:10.1523/JNEURO SCI.5216-05.2006
157. Fedorenko O, Strutz-Seebohm N, Henrion U, Ureche ON, Lang F, Seebohm G, Lang UE (2008) A schizophrenia-linked mutation in PIP5K2A fails to activate neuronal M channels. Psychopharmacology 199(1):47-54. doi:10.1007/s00213-008-1095-x
158. Wildburger NC, Laezza F (2012) Control of neuronal ion channel function by glycogen synthase kinase-3: new prospective for an old kinase. Frontiers Mol Neurosci 5:80. doi:10.3389/fn mol.2012.00080
159. Yin L, Wang J, Klein PS, Lazar MA (2006) Nuclear receptor Rev-erbalpha is a critical lithium-sensitive component of the circadian clock. Science 311(5763):1002-1005. doi:10.1126/science.1121613
160. Padiath QS, Paranjpe D, Jain S, Sharma VK (2004) Glycogen synthase kinase 3beta as a likely target for the action of lithium on circadian clocks. Chronobiol Int 21(1):43-55
161. Kozikowski AP, Gunosewoyo H, Guo S, Gaisina IN, Walter RL, Ketcherside A, McClung CA, Mesecar AD, Caldarone B (2011) Identification of a glycogen synthase kinase-3beta inhibitor that attenuates hyperactivity in CLOCK mutant mice. Chem Med Chem 6(9):1593-1602. doi:10.1002/cmdc.201100188
162. Zhou R, Yuan P, Wang Y, Hunsberger JG, Elkahloun A, Wei Y, Damschroder-Williams P, Du J, Chen G, Manji HK (2009) Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 34(6):1395-1405. doi:10.1038/npp. 2008.131
163. Kishimoto M, Ujike H, Okahisa Y, Kotaka T, Takaki M, Kodama M, Inada T, Yamada M, Uchimura N, Iwata N, Sora I, Iyo M, Ozaki N, Kuroda S (2008) The Frizzled 3 gene is associated with methamphetamine psychosis in the Japanese population. Behav Brain Funct 4:37. doi:10.1186/1744-9081-4-37
164. Lovestone S, Killick R, Di Forti M, Murray R (2007) Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci 30(4):142-149. doi:10.1016/j.tins.2007.02.002
165. Proitsi P, Li T, Hamilton G, Di Forti M, Collier D, Killick R, Chen R, Sham P, Murray R, Powell J, Lovestone S (2008) Positional pathway screen of wnt signaling genes in schizophrenia: association with DKK4. Biol Psychiatry 63(1):13-16. doi:10.1016/j.biopsych.2007.03.014
166. Cui DH, Jiang KD, Jiang SD, Xu YF, Yao H (2005) The tumor suppressor adenomatous polyposis coli gene is associated with susceptibility to schizophrenia. Mol Psychiatry 10(7):669-677. doi:10.1038/sj.mp. 4001653
167. Glatt SJ, Everall IP, Kremen WS, Corbeil J, Sasik R, Khanlou N, Han M, Liew CC, Tsuang MT (2005) Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBP1 up-regulation in schizophrenia. Proc Natl Acad Sci USA 102(43):15533-15538. doi:10.1073/p nas.0507666102
168. Kozlovsky N, Nadri C, Agam G (2005) Low GSK-3beta in schizophrenia as a consequence of neurodevelopmental insult. Eur Neuropsychopharmacol 15(1):1-11. doi:10.1016/j.euroneuro.2004.02.003
169. Carman JS, Bigelow LB, Wyatt RJ (1981) Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. J Clin Psychiatry 42(3):124-128
170. Wolff-Menzler C, Hasan A, Malchow B, Falkai P, Wobrock T (2010) Combination therapy in the treatment of schizophrenia. Pharmacopsychiatry 43(4):122-129. doi:10.105 5/s-0030-1249097
171. Porteous DJ, Millar JK, Brandon NJ, Sawa A (2011) DISC1 at 10: connecting psychiatric genetics and neuroscience. Trends Mol Med 17(12):699-706. doi:10.1016/j.molmed.2011.09.002
172. Blackwood DH, Fordyce A, Walker MT, St Clair DM, Porteous DJ, Muir WJ (2001) Schizophrenia and affective disorderscosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet 69(2):428-433
173. Marin O (2012) Interneuron dysfunction in psychiatric disorders. Nat Rev Neurosci 13(2):107-120. doi:10.1038/nrn3155
174. Kim JY, Liu CY, Zhang F, Duan X, Wen Z, Song J, Feighery E, Lu B, Rujescu D, St Clair D, Christian K, Callicott JH, Weinberger DR, Song H, Ming GL (2012) Interplay between DISC1 and GABA signaling regulates neurogenesis in mice and risk for schizophrenia. Cell 148(5):1051-1064. doi:10.1016/j. cell.2011.12.037
175. Steinecke A, Gampe C, Valkova C, Kaether C, Bolz J (2012) Disrupted-in-Schizophrenia 1 (DISC1) is necessary for the correct migration of cortical interneurons. J Neurosci 32(2):738-745. doi:10.1523/JNEUROSCI.5036-11.2012
176. Mao Y, Ge X, Frank CL, Madison JM, Koehler AN, Doud MK, Tassa C, Berry EM, Soda T, Singh KK, Biechele T, Petryshen TL, Moon RT, Haggarty SJ, Tsai LH (2009) Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell 136(6):1017-1031. doi:10.1016/j.cell.2008.12.044
177. Singh KK, Ge X, Mao Y, Drane L, Meletis K, Samuels BA, Tsai LH (2010) Dixdc1 is a critical regulator of DISC1 and embryonic cortical development. Neuron 67(1):33-48. doi:10.1016/j. neuron. 2010.06.002
178. Kivimae S, Martin PM, Kapfhamer D, Ruan Y, Heberlein U, Rubenstein JL, Cheyette BN (2011) Abnormal behavior in mice mutant for the Disc1 binding partner, Dixdc1. Transl psychiatry 1:e43. doi:10.1038/tp. 2011.41
179. Liu YT, Dan QJ, Wang J, Feng Y, Chen L, Liang J, Li Q, Lin SC, Wang ZX, Wu JW (2011) Molecular basis of Wnt activation via the DIX domain protein Ccd1. J Biol Chem 286(10):8597-8608. doi: 10.1074/jbc. M110.186742
180. Flores R 3rd, Hirota Y, Armstrong B, Sawa A, Tomoda T (2011) DISC1 regulates synaptic vesicle transport via a lithium-sensitive pathway. Neurosci Res 71(1):71-77. doi:10.1016/j.neures.2011.05.014
181. Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O (2010) miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants. Science 329(5998):1537-1541. doi:10.1126/science.1193692
182. Launay JM, Mouillet-Richard S, Baudry A, Pietri M, Kellermann O (2011) Raphe-mediated signals control the hippocampal response to SRI antidepressants via miR-16. Transl psychiatry 1:e56. doi:10.1038/tp. 2011.54
183. Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B, Cowburn RF (1999) Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 58(9):1010-1019
184. Zhang Z, Hartmann H, Do VM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Sommer B, Van De Wetering M, Clevers H, Saftig P, De Strooper B, He X, Yankner BA (1998) Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 395(6703):698-702. doi:10.1038/27208
185. Alvarez AR, Godoy JA, Mullendorff K, Olivares GH, Bronfman M, Inestrosa NC (2004) Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. Exp Cell Res 297(1):186-196. doi:10.1016/j.yexcr.2004.02.028
186. De Ferrari GV, Chacon MA, Barria MI, Garrido JL, Godoy JA, Olivares G, Reyes AE, Alvarez A, Bronfman M, Inestrosa NC (2003) Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol psychiatry 8(2):195-208. doi:10.1038/sj.mp. 4001208
187. Phiel CJ, Wilson CA, Lee VM, Klein PS (2003) GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423(6938):435-439. doi:10.1038/nature01640
188. Sofola O, Kerr F, Rogers I, Killick R, Augustin H, Gandy C, Allen MJ, Hardy J, Lovestone S, Partridge L (2010) Inhibition of GSK-3 ameliorates Abeta pathology in an adultonset Drosophila model of Alzheimer's disease. PLoS Genet 6(9):e1001087. doi:10.1371/journal.pgen. 1001087
189. Sun X, Sato S, Murayama O, Murayama M, Park JM, Yamaguchi H, Takashima A (2002) Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci Lett 321(1-2):61-64
190. Medina M, Garrido JJ, Wandosell FG (2011) Modulation of GSK-3 as a therapeutic strategy on tau pathologies. Frontiers Mol Neurosci 4:24. doi:10.3389/fnmol.2011.00024
191. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gaynor K, Wang L, La Francois J, Feinstein B, Burns M, Krishnamurthy P, Wen Y, Bhat R, Lewis J, Dickson D, Duff K (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 102(19):6990-6995. doi:10.1073/p nas.0500466102
192. Perez M, Hernandez F, Lim F, Diaz-Nido J, Avila J (2003) Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimer's Dis 5(4):301-308
193. Nakashima H, Ishihara T, Suguimoto P, Yokota O, Oshima E, Kugo A, Terada S, Hamamura T, Trojanowski JQ, Lee VM, Kuroda S (2005) Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol 110(6):547-556. doi:10.1007/s00401-005-1087-4
194. Rametti A, Esclaire F, Yardin C, Cogne N, Terro F (2008) Lithium down-regulates tau in cultured cortical neurons: a possible mechanism of neuroprotection. Neurosci Lett 434(1):93-98. doi:10.1016/j.neulet.2008.01.034
195. Leroy K, Ando K, Heraud C, Yilmaz Z, Authelet M, Boeynaems JM, Buee L, De Decker R, Brion JP (2010) Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology. J Alzheimer's Dis 19(2):705-719. doi:10.3233/JAD-2010-1276
196. Rockenstein E, Torrance M, Adame A, Mante M, Baron P, Rose JB, Crews L, Masliah E (2007) Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 27(8):1981-1991. doi:10.1523/JNEURO SCI.4321-06.2007
197. Toledo EM, Inestrosa NC (2010) Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of alzheimer's disease. Mol Psychiatry 15(3):272-285. doi:10.1038/mp. 2009.72
198. Li HL, Wang HH, Liu SJ, Deng YQ, Zhang YJ, Tian Q, Wang XC, Chen XQ, Yang Y, Zhang JY, Wang Q, Xu H, Liao FF, Wang JZ (2007) Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer's neurodegeneration. Proc Natl Acad Sci USA 104(9):3591-3596. doi:10.1073/pnas.0609303104
199. Martin L, Page G, Terro F (2011) Tau phosphorylation and neuronal apoptosis induced by the blockade of PP2A preferentially involve GSK3beta. Neurochem Int 59(2):235-250. doi:10.1016/j.neuint.2011.05.010
200. Tsuji S, Morinobu S, Tanaka K, Kawano K, Yamawaki S (2003) Lithium, but not valproate, induces the serine/threonine phosphatase activity of protein phosphatase 2A in the rat brain, without affecting its expression. J Neural Transm 110(4):413-425. doi:10.1007/s00702-002-0798-0
201. Martin L, Magnaudeix A, Esclaire F, Yardin C, Terro F (2009) Inhibition of glycogen synthase kinase-3beta downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A. Brain Res 1252:66-75. doi:10.1016/j.brainres.2008.11.057
202. Chacon MA, Varela-Nallar L, Inestrosa NC (2008) Frizzled-1 is involved in the neuroprotective effect of Wnt3a against Abeta oligomers. J Cell Physiol 217(1):215-227. doi:10.1002/jcp. 21497
203. Magdesian MH, Carvalho MM, Mendes FA, Saraiva LM, Juliano MA, Juliano L, Garcia-Abreu J, Ferreira ST (2008) Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling. J Bio Chem 283(14):9359-9368. doi:10.1074/jbc. M707108200
204. Caricasole A, Copani A, Caraci F, Aronica E, Rozemuller AJ, Caruso A, Storto M, Gaviraghi G, Terstappen GC, Nicoletti F (2004) Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in alzheimer's brain. J Neurosci 24(26):6021-6027. doi:10.1523/JNE UROSCI.1381-04.2004
205. Scali C, Caraci F, Gianfriddo M, Diodato E, Roncarati R, Pollio G, Gaviraghi G, Copani A, Nicoletti F, Terstappen GC, Caricasole A (2006) Inhibition of Wnt signaling, modulation of tau phosphorylation and induction of neuronal cell death by DKK1. Neurobiol Dis 24(2):254-265. doi:10.1016/j.nbd.2006.06.016
206. Purro SA, Dickins EM, Salinas PC (2012) The secreted Wnt antagonist Dickkopf-1 is required for amyloid beta-mediated synaptic loss. J Neurosci 32(10):3492-3498. doi:10.1523/JNEU ROSCI.4562-11.2012
207. Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, La Ferla FM (2006) M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 49(5):671-682. doi:10.1016/j.neuron. 2006.01.020
208. Wang CY, Zheng W, Wang T, Xie JW, Wang SL, Zhao BL, Teng WP, Wang ZY (2011) Huperzine A activates Wnt/beta-catenin signaling and enhances the nonamyloidogenic pathway in an alzheimer transgenic mouse model. Neuropsychopharmacology 36(5):1073-1089. doi:10.1038/npp. 2010.245
209. Farias GG, Godoy JA, Hernandez F, Avila J, Fisher A, Inestrosa NC (2004) M1 muscarinic receptor activation protects neurons from beta-amyloid toxicity. A role for Wnt signaling pathway. Neurobio Dis 17(2):337-348. doi:10.1016/j.nbd.2004.07.016
210. Jope RS, Yuskaitis CJ, Beurel E (2007) Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 32(4-5):577-595. doi:10.1007/s11064-006-9128-5
211. Farias GG, Godoy JA, Vazquez MC, Adani R, Meshulam H, Avila J, Amitai G, Inestrosa NC (2005) The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components. Neurobiol Dis 18(1):176-183. doi:10.1016/j.nbd.2004.09.012
212. Kitazawa M, Cheng D, Tsukamoto MR, Koike MA, Wes PD, Vasilevko V, Cribbs DH, La Ferla FM (2011) Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal beta-catenin pathway function in an Alzheimer's disease model. J Immunol 187(12):6539-6549. doi:10.40 49/jimmunol.1100620
213. Wang X, Liu P, Zhu H, Xu Y, Ma C, Dai X, Huang L, Liu Y, Zhang L, Qin C (2009) miR-34a, a microRNA up-regulated in a double transgenic mouse model of alzheimer's disease, inhibits bcl2 translation. Brain Res Bull 80(4-5):268-273. doi:10.1016/j.brainresbull.2009.08.006
214. Terao T, Nakano H, Inoue Y, Okamoto T, Nakamura J, Iwata N (2006) Lithium and dementia: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 30(6):1125-1128. doi:10.1016/j.pnpbp. 2006.04.020
215. Nunes PV, Forlenza OV, Gattaz WF (2007) Lithium and risk for alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry: J Mental Sci 190:359-360. doi:10.1192/bjp. bp. 106.029868
216. Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF (2011) Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry: J Mental Sci 198(5):351-356. doi:10.1192/bjp. bp. 110.080044
217. Kessing LV, Sondergard L, Forman JL, Andersen PK (2008) Lithium treatment and risk of dementia. Arch Gen Psychiatry 65(11):1331-1335. doi:10.1001/archpsyc.65.11.1331
218. Leyhe T, Eschweiler GW, Stransky E, Gasser T, Annas P, Basun H, Laske C (2009) Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. J Alzheimer's Dis 16(3):649-656. doi:10.3233/JAD-2009-1004
219. Macdonald A, Briggs K, Poppe M, Higgins A, Velayudhan L, Lovestone S (2008) A feasibility and tolerability study of lithium in Alzheimer's disease. Int J Geriatr Psychiatry 23(7):704-711. doi:10.1002/gps.1964
220. Young AH (2011) More good news about the magic ion: lithium may prevent dementia. Br J Psychiatry J Ment Sci 198(5):336-337. doi:10.1192/bjp. bp. 110.082875
221. Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis of alzheimer's disease. J Neurochem 104(6):1433-1439. doi:10.1111/j.1471-4159.2007.05194.x
222. Berger Z, Ttofi EK, Michel CH, Pasco MY, Tenant S, Rubinsztein DC, O'Kane CJ (2005) Lithium rescues toxicity of aggregate-prone proteins in drosophila by perturbing Wnt pathway. Hum Mol Genet 14(20):3003-3011. doi:10.1093/hmg/ddi331
223. Carmichael J, Sugars KL, Bao YP, Rubinsztein DC (2002) Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the huntington's disease mutation. J Biol Chem 277(37):33791-33798. doi:10.1074/jbc. M204861200
224. Senatorov VV, Ren M, Kanai H, Wei H, Chuang DM (2004) Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of huntington's disease. Mol Psychiatry 9(4):371-385. doi:10.1038/sj.mp. 4001463
225. Wei H, Qin ZH, Senatorov VV, Wei W, Wang Y, Qian Y, Chuang DM (2001) Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of huntington's disease. Neuroscience 106(3):603-612
226. Crespo-Biel N, Camins A, Pallas M, Canudas AM (2009) Evidence of calpain/cdk5 pathway inhibition by lithium in 3-nitropropionic acid toxicity in vivo and in vitro. Neuropharmacology 56(2):422-428. doi:10.1016/j.neuropharm.2008.09.012
227. Sarkar S, Krishna G, Imarisio S, Saiki S, O'Kane CJ, Rubinsztein DC (2008) A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet 17(2):170-178. doi:10.1093/hmg/ddm294
228. Godin JD, Poizat G, Hickey MA, Maschat F, Humbert S (2010) Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington's disease. EMBO J 29(14):2433-2445. doi:10.1038/emboj.2010.117
229. Wood NI, Morton AJ (2003) Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation. Brain Res Bull 61(4):375-383
230. Chiu CT, Liu G, Leeds P, Chuang DM (2011) Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology 36(12):2406-2421. doi:10.1038/npp. 2011.128
231. Leng Y, Liang MH, Ren M, Marinova Z, Leeds P, Chuang DM (2008) Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 28(10):2576-2588. doi:10.1523/JNEUROSCI.5467-07.2008
232. Pouladi MA, Brillaud E, Xie Y, Conforti P, Graham RK, Ehrnhoefer DE, Franciosi S, Zhang W, Poucheret P, Compte E, Maurel JC, Zuccato C, Cattaneo E, Neri C, Hayden MR (2012) NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease. Neurobiol Dis 48(3):282-289. doi:10.1016/j.nbd.2012.06.026
233. Vazey EM, Connor B (2010) Differential fate and functional outcome of lithium chloride primed adult neural progenitor cell transplants in a rat model of Huntington disease. Stem cell Res Ther 1(5):41. doi:10.1186/scrt41
234. Berwick DC, Harvey K (2012) The importance of Wnt signalling for neurodegeneration in Parkinson's disease. Biochem Soc Trans 40(5):1123-1128. doi:10.1042/BST20120122
235. Chen G, Bower KA, Ma C, Fang S, Thiele CJ, Luo J (2004) Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J 18(10):1162-1164. doi:10.1096/fj.04-1551fje
236. Duka T, Duka V, Joyce JN, Sidhu A (2009) Alpha-synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J 23(9):2820-2830. doi:10. 1096/fj.08-120410
237. King TD, Bijur GN, Jope RS (2001) Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and attenuated by lithium. Brain Res 919(1):106-114
238. Castro AA, Ghisoni K, Latini A, Quevedo J, Tasca CI, Prediger RD (2012) Lithium and valproate prevent olfactory discrimination and short-term memory impairments in the intranasal 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) rat model of Parkinson's disease. Behav Brain Res 229(1):208-215. doi:10.1016/j.bbr.2012.01.016
239. Koh SH, Song C, Noh MY, Kim HY, Lee KY, Lee YJ, Kim J, Kim SH, Kim HT (2008) Inhibition of glycogen synthase kinase-3 reduces L-DOPA-induced neurotoxicity. Toxicology 247(2-3):112-118. doi:10.1016/j.tox.2008.02.007
240. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Deleidi M, Serapide MF, Pluchino S, Marchetti B (2012) Plasticity of subventricular zone neuroprogenitors in MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) mouse model of Parkinson's disease involves cross talk between inflammatory and Wnt/beta-catenin signaling pathways: functional consequences for neuroprotection and repair. J Neurosci 32(6):2062-2085. doi:10.1523/JNEUROSCI.5259-11.2012
241. Youdim MB, Arraf Z (2004) Prevention of MPTP (N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Neuropharmacology 46(8):1130-1140. doi:10.1016/j.neuroph arm.2004.02.005
242. Arraf Z, Amit T, Youdim MB, Farah R (2012) Lithium and oxidative stress lessons from the MPTP model of Parkinson's disease. Neurosci Lett 516(1):57-61. doi:10.1016/j.neulet.2012.03.055
243. Kim YH, Rane A, Lussier S, Andersen JK (2011) Lithium protects against oxidative stress-mediated cell death in alpha-synuclein-overexpressing in vitro and in vivo models of Parkinson's disease. J Neurosci Res 89(10):1666-1675. doi:10.1002/jnr.22700
244. Li XZ, Chen XP, Zhao K, Bai LM, Zhang H, Zhou XP (2013) Therapeutic effects of valproate combined with lithium carbonate on MPTP-induced Parkinsonism in mice: possible mediation through enhanced autophagy. Int J Neurosc 123(2):73-79. doi:10.3109/00207454.2012.729234
245. Xiong N, Jia M, Chen C, Xiong J, Zhang Z, Huang J, Hou L, Yang H, Cao X, Liang Z, Sun S, Lin Z, Wang T (2011) Potential autophagy enhancers attenuate rotenone-induced toxicity in SH-SY5Y. Neuroscience 199:292-302. doi:10.1016/j. neuroscience.2011.10.031
246. Yong Y, Ding H, Fan Z, Luo J, Ke ZJ (2011) Lithium fails to protect dopaminergic neurons in the 6-OHDA model of Parkinson's disease. Neurochem Res 36(3):367-374. doi:10.1007/s11064-010-0368-z
247. Dun Y, Yang Y, Xiong Z, Feng M, Zhang Y, Wang M, Xiang J, Li G, Ma R (2012) Induction of Dickkopf-1 contributes to the neurotoxicity of MPP (+) in PC12 cells via inhibition of the canonical Wnt signaling pathway. Neuropharmacology 67C: 168-175. doi:10.1016/j.neuropharm.2012.10.031
248. Holroyd S, Smith D (1995) Disabling parkinsonism due to lithium: a case report. J Geriatr Psychiatry Neurol 8(2):118-119
249. Loane DJ, Faden AI (2010) Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies. Trends Pharmacol Sci 31(12):596-604. doi:10.1016/j. tips.2010.09.005
250. Homsi S, Piaggio T, Croci N, Noble F, Plotkine M, Marchand-Leroux C, Jafarian-Tehrani M (2010) Blockade of acute microglial activation by minocycline promotes neuroprotection and reduces locomotor hyperactivity after closed head injury in mice: a twelve-week follow-up study. J Neurotrauma 27(5):911-921. doi:10.1089/neu.2009.1223
251. Siopi E, Calabria S, Plotkine M, Marchand-Leroux C, Jafarian-Tehrani M (2012) Minocycline restores olfactory bulb volume and olfactory behavior after traumatic brain injury in mice. J Neurotrauma 29(2):354-361. doi:10.1089/neu.2011.2055
252. Siopi E, Cho AH, Homsi S, Croci N, Plotkine M, Marchand-Leroux C, Jafarian-Tehrani M (2011) Minocycline restores sAPPalpha levels and reduces the late histopathological consequences of traumatic brain injury in mice. J Neurotrauma 28(10):2135-2143. doi:10.1089/neu.2010.1738
253. Siopi E, Llufriu-Daben G, Cho AH, Vidal-Lletjos S, Plotkine M, Marchand-Leroux C, Jafarian-Tehrani M (2012) Etazolate, an alpha-secretase activator, reduces neuroinflammation and offers persistent neuroprotection following traumatic brain injury in mice. Neuropharmacology 67C: 183-192. doi:10.1016/j.neurop harm.2012.11.009
254. Siopi E, Llufriu-Daben G, Fanucchi F, Plotkine M, Marchand-Leroux C, Jafarian-Tehrani M (2012) Evaluation of late cognitive impairment and anxiety states following traumatic brain injury in mice: the effect of minocycline. Neurosci Lett 511(2):110-115. doi:10.1016/j.neulet.2012.01.051
255. Vink R, Nimmo AJ (2009) Multifunctional drugs for head injury. Neurotherapeutics 6(1):28-12. doi:10.1016/j.nurt.2008.10.036
256. Shapira M, Licht A, Milman A, Pick CG, Shohami E, Eldar-Finkelman H (2007) Role of glycogen synthase kinase-3beta in early depressive behavior induced by mild traumatic brain injury. Mol Cell Neurosci 34(4):571-577. doi:10.1016/j.mcn. 2006.12.006
257. Zhu ZF, Wang QG, Han BJ, William CP (2010) Neuroprotective effect and cognitive outcome of chronic lithium on traumatic brain injury in mice. Brain Res Bull 83(5):272-277. doi:10.1016/j.brainresbull.2010.07.008
258. Yu F, Wang Z, Tchantchou F, Chiu CT, Zhang Y, Chuang DM (2012) Lithium ameliorates neurodegeneration, suppresses neuroinflammation, and improves behavioral performance in a mouse model of traumatic brain injury. J Neurotrauma 29(2):362-374. doi:10.1089/neu.2011.1942
259. Yu F, Zhang Y, Chuang DM (2012) Lithium reduces BACE1 overexpression, beta amyloid accumulation, and spatial learning deficits in mice with traumatic brain injury. J Neurotrauma 29(13):2342-2351. doi:10.1089/neu.2012.2449
260. Dash PK, Johnson D, Clark J, Orsi SA, Zhang M, Zhao J, Grill RJ, Moore AN, Pati S (2011) Involvement of the glycogen synthase kinase-3 signaling pathway in TBI pathology and neurocognitive outcome. PLoS One 6(9):e24648. doi:10.1371/journal.pone.0024648
261. Deb S, Crownshaw T (2004) The role of pharmacotherapy in the management of behaviour disorders in traumatic brain injury patients. Brain Injury 18(1):1-31. doi:10.1080/0269905031000110463
262. Feigenson K, Reid M, See J, Crenshaw EB 3rd, Grinspan JB (2009) Wnt signaling is sufficient to perturb oligodendrocyte maturation. Mol Cell Neurosci 42(3):255-265. doi:10.1016/j.mcn. 2009.07.010
263. Levine S, Saltzman A (1991) Inhibition of experimental allergic encephalomyelitis by lithium chloride: specific effect or nonspecific stress? Immunopharmacology 22(3):207-213
264. De Sarno P, Axtell RC, Raman C, Roth KA, Alessi DR, Jope RS (2008) Lithium prevents and ameliorates experimental autoimmune encephalomyelitis. J Immunol 181(1):338-345
265. Fancy SP, Harrington EP, Yuen TJ, Silbereis JC, Zhao C, Baranzini SE, Bruce CC, Otero JJ, Huang EJ, Nusse R, Franklin RJ, Rowitch DH (2011) Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination. Nat Neurosci 14(8):1009-1016. doi:10.1038/nn. 2855
266. Azim K, Butt AM (2011) GSK3beta negatively regulates oligodendrocyte differentiation and myelination in vivo. Glia 59(4):540-553. doi:10.1002/glia.21122
267. Galimberti D, Macmurray J, Scalabrini D, Fenoglio C, De Riz M, Comi C, Comings D, Cortini F, Villa C, Serpente M, Cantoni C, Ridolfi E, Fardipoor MH, Leone M, Monaco F, Bresolin N, Scarpini E (2011) GSK3beta genetic variability in patients with Multiple Sclerosis. Neurosci Lett 497(1):46-48. doi:10.1016/j.neulet.2011.04.024
268. Kumar S, Mattan NS, De Vellis J (2006) Canavan disease: a white matter disorder. Ment Retard Dev Disabil Res Rev 12(2):157-165. doi:10.1002/mrdd.20108
269. Baslow MH, Kitada K, Suckow RF, Hungund BL, Serikawa T (2002) The effects of lithium chloride and other substances on levels of brain N-acetyl-L-aspartic acid in Canavan disease-like rats. Neurochem Res 27(5):403-406
270. Assadi M, Janson C, Wang DJ, Goldfarb O, Suri N, Bilaniuk L, Leone P (2010) Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease. Eur J Paediatr Neurol 14(4):354-359. doi:10.1016/j.ejpn. 2009.11.006
271. Janson CG, Assadi M, Francis J, Bilaniuk L, Shera D, Leone P (2005) Lithium citrate for Canavan disease. Pediatr Neurol 33(4):235-243. doi:10.1016/j.pediatrneurol.2005.04.015
272. Solsona MD, Fernandez LL, Boquet EM, Andres JL (2012) Lithium citrate as treatment of Canavan disease. Clin Neuropharmacol 35(3):150-151. doi:10.1097/WNF.0b013e318 2515c9d
273. Benedetti F, Absinta M, Rocca MA, Radaelli D, Poletti S, Bernasconi A, Dallaspezia S, Pagani E, Falini A, Copetti M, Colombo C, Comi G, Smeraldi E, Filippi M (2011) Tract-specific white matter structural disruption in patients with bipolar disorder. Bipolar Disord 13(4):414-424. doi:10.1111/j.1399-5618.2011.00938.x
274. Benedetti F, Bollettini I, Barberi I, Radaelli D, Poletti S, Locatelli C, Pirovano A, Lorenzi C, Falini A, Colombo C, Smeraldi E (2013) Lithium and GSK3-beta promoter gene variants influence white matter microstructure in bipolar disorder. Neuropsychopharmacology 38(2):313-327. doi:10.1038/npp. 2012.172
275. Adityanjee Munshi KR, Thampy A (2005) The syndrome of irreversible lithium-effectuated neurotoxicity. Clin Neuropharmacol 28(1):38-49
276. Hashimoto R, Senatorov V, Kanai H, Leeds P, Chuang DM (2003) Lithium stimulates progenitor proliferation in cultured brain neurons. Neuroscience 117(1):55-61
277. Wexler EM, Geschwind DH, Palmer TD (2008) Lithium regulates adult hippocampal progenitor development through canonical Wnt pathway activation. Mol psychiatry 13(3):285-292. doi:10.1038/sj.mp. 4002093
278. Bianchi P, Ciani E, Contestabile A, Guidi S, Bartesaghi R (2010) Lithium restores neurogenesis in the subventricular zone of the Ts65Dn mouse, a model for Down syndrome. Brain Pathol 20(1):106-118. doi:10.1111/j.1750-3639.2008.00246.x
279. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK (2000) Enhancement of hippocampal neurogenesis by lithium. J Neurochem 75(4):1729-1734
280. Son H, Yu IT, Hwang SJ, Kim JS, Lee SH, Lee YS, Kaang BK (2003) Lithium enhances long-term potentiation independently of hippocampal neurogenesis in the rat dentate gyrus. J Neurochem 85(4):872-881
281. Yan XB, Hou HL, Wu LM, Liu J, Zhou JN (2007) Lithium regulates hippocampal neurogenesis by ERK pathway and facilitates recovery of spatial learning and memory in rats after transient global cerebral ischemia. Neuropharmacology 53(4):487-495. doi:10.1016/j.neuropharm.2007.06.020
282. Rong H, Liu TB, Yang KJ, Yang HC, Wu DH, Liao CP, Hong F, Yang HZ, Wan F, Ye XY, Xu D, Zhang X, Chao CA, Shen QJ (2011) MicroRNA-134 plasma levels before and after treatment for bipolar mania. J Psychiatr Res 45(1):92-95. doi:10.1016/j.jp sychires.2010.04.028
283. Saito Y, Saito H (2012) MicroRNAs in cancers and neurodegenerative disorders. Frontiers Genet 3:194. doi:10.3389/fg ene.2012.00194
284. Bartzokis G (2012) Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments. Neuropharmacology 62(7):2137-2153. doi:10.1016/j.neuroph arm.2012.01.015
285. Amit S, Hatzubai A, Birman Y, Andersen JS, Ben-Shushan E, Mann M, Ben-Neriah Y, Alkalay I (2002) Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev 16(9):1066-1076. doi:10.1101/gad.230302
286. Yanagawa S, Matsuda Y, Lee JS, Matsubayashi H, Sese S, Kadowaki T, Ishimoto A (2002) Casein kinase I phosphorylates the Armadillo protein and induces its degradation in Drosophila. EMBO J 21(7):1733-1742. doi:10.1093/emboj/21.7.1733
287. Zeng X, Tamai K, Doble B, Li S, Huang H, Habas R, Okamura H, Woodgett J, He X (2005) A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 438(7069):873-877. doi:10.1038/nature04185
288. Davidson G, Shen J, Huang YL, Su Y, Karaulanov E, Bartscherer K, Hassler C, Stannek P, Boutros M, Niehrs C (2009) Cell cycle control of wnt receptor activation. Dev Cell 17(6):788-799. doi:10.1016/j.devcel.2009.11.006
289. Taelman VF, Dobrowolski R, Plouhinec JL, Fuentealba LC, Vorwald PP, Gumper I, Sabatini DD, De Robertis EM (2010) Wnt signaling requires sequestration of glycogen synthase kinase 3 inside multivesicular endosomes. Cell 143(7):1136-1148. doi:10.1016/j.cell.2010.11.034
290. Qin Y, Li L, Pan W, Wu D (2009) Regulation of phosphatidylinositol kinases and metabolism by Wnt3a and Dvl. J Biol Chem 284(34):22544-22548. doi:10.1074/jbc. M109.014399
291. Feigin ME, Malbon CC (2007) RGS19 regulates Wnt-betacatenin signaling through inactivation of Galpha (o). J Cell Sci 120(Pt 19):3404-3414. doi:10.1242/jcs.011254
292. Egger-Adam D, Katanaev VL (2010) The trimeric G protein Go inflicts a double impact on axin in the Wnt/frizzled signaling pathway. Dev Dyn 239(1):168-183. doi:10.1002/dvdy.22060
293. Jung H, Kim HJ, Lee SK, Kim R, Kopachik W, Han JK, Jho EH (2009) Negative feedback regulation of Wnt signaling by Gbetagamma-mediated reduction of Dishevelled. Exp Mol Med 41(10):695-706. doi:10.3858/emm.2009.41.10.076
294. Kramps T, Peter O, Brunner E, Nellen D, Froesch B, Chatterjee S, Murone M, Zullig S, Basler K (2002) Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex. Cell 109(1):47-60
295. Parker DS, Jemison J, Cadigan KM (2002) Pygopus, a nuclear PHD-finger protein required for Wingless signaling in Drosophila. Development 129(11):2565-2576
296. Gan XQ, Wang JY, Xi Y, Wu ZL, Li YP, Li L (2008) Nuclear Dvl, c-Jun, beta-catenin, and TCF form a complex leading to stabilization of beta-catenin-TCF interaction. J Cell Biol 180(6):1087-1100. doi:10.1083/jcb.200710050
297. Parker DS, Ni YY, Chang JL, Li J, Cadigan KM (2008) Wingless signaling induces widespread chromatin remodeling of target loci. Mol Cell Biol 28(5):1815-1828. doi:10.1128/MCB.01230-07
298. Sierra J, Yoshida T, Joazeiro CA, Jones KA (2006) The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes. Genes Dev 20(5):586-600. doi:10.1101/gad.1385806
299. Alberts AS (2002) Diaphanous-related Formin homology proteins. Curr Biol 12(23):R796